Screening for pulmonary hypertension in systemic sclerosis: The longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001

Rheumatology

Volumn 44, Issue 3, 2005, Pages 366-371

  Hesselstrand, Roger ^a   Ekman, R ^b   Eskilsson, J ^a   Isaksson, A ^a   Scheja, A ^a   Ohlin A K ^a   Akesson A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ProBNP; Pulmonary arterial hypertension; Pulmonary arterial systolic pressure; Systemic sclerosis; Tricuspid gradient

Indexed keywords

AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CYCLOPHOSPHAMIDE; ILOPROST; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; TRICUSPID VALVE;

AGE FACTORS; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; CARBON MONOXIDE; ECHOCARDIOGRAPHY, DOPPLER; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SCLERODERMA, SYSTEMIC; THROMBOMODULIN; TRICUSPID VALVE; TRICUSPID VALVE INSUFFICIENCY; VON WILLEBRAND FACTOR;

EID: 14944346766     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh486     Document Type: Article

References (37)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-25.
2. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
3. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
4. Lee P, Langevitz P, Alderdice CA et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
5. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988;15:276-83.
6. Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971;30:581-58.
7. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
8. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
9. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
10. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003;42:534-40.
11. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
12. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
13. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
14. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
15. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
16. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
17. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
18. Battle RW, Davitt MA, Cooper SM et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
19. Yamane K, Ihn H, Asano Y et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 2000;39:1269-71.
20. Nagaya N, Nishikimi T, Okano Y et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8.
21. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
22. Wakaumi M, Shiga T, Nozaki K et al. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report. Heart Vessels 2000;15:144-6.
23. Bartosik I, Eskilsson J, Scheja A, Akesson A. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma - a pilot study. Br J Rheumatol 1996;35:1187-8.
24. Sakamaki F, Kyotani S, Nagaya N et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000;102:2720-5.
25. Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 2000;59:132-34.
26. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998;114:1276-82.
27. Masi AT, Medsger TA Jr, Altman RD et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
28. Bartosik I, Eskilsson J, Ekman R, Akesson A, Scheja A. Correlation between plasma concentrations of calcitonin gene related peptide and pulmonary pressure in patients with systemic sclerosis. Ann Rheum Dis 2002;61:261-3.
29. Johnston N, Jernberg T, Lindahl B et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004;37:210-6.
30. Edvinsson L, Ekman R, Thulin T. Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man. J Hum Hypertens 1989; 3:267-70.
31. Ohlin AK, Morser J, Ohlin H. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 1996; 82:313-22.
32. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
33. Mukerjec D, St George D, Knight C et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-6.
34. Dib JC, Abergel E, Rovani C, Raffoul H, Diebold B. The age of the patient should be taken into account when interpreting Doppler assessed pulmonary artery pressures. J Am Soc Echocardiogr 1997;10:72-3.
35. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62: 1088-93.
36. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynard's phenomenon. Lancet 1990;336:1530-3.
37. Tjen AL, Ekman R, Lippton H, Cary J, Keith I. CGRP and somatostatin modulate chronic hypoxic pulmonary hypertension. Am J Physiol 1992;263:H681-H690.